Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee
“We are very pleased to welcome Drs. Slaoui and Verwiel to our Board of Directors. They bring decades of scientific, operational, business and strategic experience in the pharmaceutical and biotech industries to Intellia. We look forward to their guidance as we continue to advance our genome editing technology to patients,” said
Dr.
Dr.
Dr. Slaoui led the company’s bioelectronics R&D strategy, including the launch of Galvani Bioelectronics, a company where he remains Chairman of the board of directors.
Dr. Slaoui has authored more than 100 scientific papers and presentations and served on the board of directors for the
Dr. Slaoui received his Ph.D. in Molecular Biology and Immunology from the Université libre de
Dr.
Dr. Verwiel possesses significant biotech and pharmaceutical experience, having been the president and CEO of
Dr. Verwiel currently serves as chairman of the board of directors of
Dr. Verwiel received a doctorate in medicine from
New Science and Technology Committee Supports Intellia’s R&D Strategy
In recognition of the company’s advances and opportunities in applying the CRISPR/Cas technology platform, Intellia’s Board of Directors is creating a new committee to the Board, the Science and Technology Committee. This committee will support the Board of Directors in its oversight and advisement of the Company’s research and development activities and scientific strategy. The Science and Technology Committee will be chaired by Dr. Slaoui, given his extensive operational, scientific and industry experience.
“Both Drs. Slaoui and Verwiel have served as board directors for key organizations and were top executives at companies that delivered innovative medicines to patients,” said
Intellia’s Board of Directors, committees, chairpersons and members include:
- Chair of the Board:
Perry Karsen - Board Members:
Perry Karsen ,Nessan Bermingham ,Caroline Dorsa , Jean-François Formela,John Leonard ,Moncef Slaoui andFrank Verwiel - Audit Committee:
Caroline Dorsa (Chair), Jean-François Formela, andFrank Verwiel - Compensation Committee: Jean-François Formela (Chair),
Caroline Dorsa ,Perry Karsen , andMoncef Slaoui - Nominating & Corporate Governance Committee:
Perry Karsen (Chair),Caroline Dorsa andFrank Verwiel - Science & Technology Committee:
Moncef Slaoui (Chair), Jean-François Formela andJohn Leonard
About
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent quarterly report on Form 10-Q filed with the
Intellia Contacts:Jennifer Mound Smoter Senior Vice President,External Affairs & Communications 857-701-1071 jenn.smoter@intelliatx.comGraeme Bell Executive Vice President, Chief Financial Officer 857-701-1081 graeme.bell@intelliatx.com